Contineum Therapeutics (CTNM) Insider Brady Buys 19,000 Shares
Todd Brady acquired 19,000 shares of Contineum Therapeutics on June 26, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Todd Brady bought 19,000 shares of Contineum Therapeutics, Inc. ($CTNM) on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CTNM is up 9.4% after 1 week, down 2.3% after 1 month and down 50.1% to date (from the $14.19 close on Jun 26, 2026).
CTNM
Contineum Therapeutics, Inc.
Key Points
- On June 26, 2026, Todd Brady bought 19,000 shares of Contineum Therapeutics, Inc. (CTNM) at a price of $14.19 per share.
- The stock has been performing well, trading near its 50-day moving average of $15.17, which is above its 200-day average of $13.67.
- Analysts maintain a strong outlook on Contineum, with a consensus rating of 'Strong Buy' and a target mean price of $22.57.
Get $CTNM trade alerts by text
We text you when insiders, Congress or big funds trade $CTNM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Contineum Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Contineum Therapeutics, Inc.
On June 26, 2026, Todd Brady bought 19,000 shares of Contineum Therapeutics, Inc. (CTNM) on the NasdaqGS. The shares were purchased at a price of $14.19 each, reflecting a total value of approximately $269,610. This purchase aligns with recent insider activity at the company, where several other insiders also made significant buys on the same day.
Other Insiders Join the Buying
On the same day, four other insiders also purchased 19,000 shares each of Contineum Therapeutics. Troy Ignelzi, Evert Schimmelpennink, Sarah Boyce, and Olivia Ware each made the same buy. This collective insider buying suggests a strong belief in the company's future prospects, especially as they develop innovative therapies for various medical conditions.
Stock Performance Context
Contineum Therapeutics' stock has been trading around $14.19, close to its 50-day moving average of $15.17. The stock is also above its 200-day average of $13.67. The company has a market cap of about $509.8 million and has seen its shares fluctuate between $8.60 and $17.79 over the past year. This activity may indicate that insiders are optimistic about the company’s future performance.
Analysts Set New Price Targets
Analysts have a positive outlook on Contineum Therapeutics. On October 15, 2026, Jones Trading maintained its 'Buy' rating with a target price of $30.00, up from a prior target of $24.00. However, Baird downgraded the stock to 'Neutral' with a target of $14.00 on October 14, down from $19.00. Overall, the consensus rating remains strong, with a target mean price of $22.57 based on seven analyst opinions, indicating confidence in the company's trajectory.
What Contineum Therapeutics, Inc. Does
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in San Diego, California. It focuses on developing small molecule therapies for conditions related to neuroscience, inflammation, and immunology. The company’s lead asset is PIPE-791, aimed at treating idiopathic pulmonary fibrosis and chronic pain.
What’s Next for Contineum
Investors will be watching for further updates from Contineum Therapeutics as the company approaches its next earnings report scheduled for October 29, 2026. The recent insider transactions reflect a strong commitment from key executives, which may be a positive indicator for the company’s future developments. Remember, this insider buying activity is based on filings that reflect past transactions and may not represent current positions.
Related Filing Alerts
Source: Todd Brady's Form 4 filing on $CTNM (Jun 26, 2026). Find the original filing: CTNM Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts